COVID-19 and MS disease-modifying therapies
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 16, 2020
- Accepted in final form April 26, 2020
- First Published May 15, 2020.
Author Disclosures
- Joseph R. Berger, MD,
- Rachel Brandstadter, MD and
- Amit Bar-Or, MD
- Joseph R. Berger, MD,
Dr. Berger serves as a consultant and/or on the PML adjudication committees of Novartis and Takeda/Millennium. He also serves on the Scientific Advisory Board ExcisionBio and Inhibikase. He is chair of the Data Safety Monitoring Board for MAPI.
NONE
Dr. Berger has received honoraria from Prime Education, AcademicCME, Arcus Medica, Eisenhower Medical Center, River West Meetings, and the MS Foundation for lectures.
Dr. Berger serves as an editorial board member of the Journal of Neurovirology, Neurology Reviews and MS and Related Disorders
NONE
Portegies P, Berger JR (Editors): HIV/AIDS and the Nervous System. In Vinken PJ, Bruyn G (Editors): Handbook of Clinical Neurology, Volume 85; Elsevier, Amsterdam, 2007.
NONE
Dr. Berger serves as a consultant to Biogen, Celgene, Dr. Reddy, EMD Serono, Genzyme/Sanofi, Merck, Novartis, Roche/Genentech, Morphic, Encycle, Novartis, and Millennium/Takeda.
NONE
NONE
NONE
1) Biogen 2) Genentech
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rachel Brandstadter, MD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Amit Bar-Or, MD
Receptos-Celgene, Advisor, Scientific Board, 2011 - Sanofi/Genzyme, Advisor, Scientific board, 2017 - Roche/Genentech, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- GSK, Advisor 2012 - 2014 Atara Therapeutics, Advisor, Scientific Board, 2017 - Guthy Jackson Greater Good Foundation, Scientific Advisor, 2008- Immune Tolerance Network - Steering Committee, 2016 -
NONE
Receptos-Celgene, Advisor, Scientific Board, 2011 - Roche/Genentech, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- Sanofi-Genzyme 2015- GSK, Advisor 2012 - 2014
(1) Neurology, Editorial Board Member, 2008-2015 (2) Clinical and Experimental Neuroimmunology, Editorial Board Member, 2010 -
NONE
NONE
NONE
Receptos-Celgene, Advisor, Scientific Board, 2011 - Roche/Genentech, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- Sanofi-genzyme - Advisor, 2015 - GSK, Advisor 2012 - 2014 Atara Therapeutics, Advisor, Scientific Board, 2017 -
NONE
NONE
NONE
(1) Novartis (2) Genzyme-Sanofi (3) Biogen (4) Merck/EMDSerono (5) Roche/Genentech
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Division of Multiple Sclerosis, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
- Correspondence
Dr. Berger joseph.berger{at}pennmedicine.upenn.edu
Article usage
Cited By...
Letters: Rapid online correspondence
- Reader response: COVID-19 and MS disease-modifying therapies
- Jonathan O. Harris, Neurologist, Jonathan Oren Harris MD LLC
Submitted July 04, 2020
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- Glossary
- Potential risks of COVID-19 to patients with MS
- The pathogen for COVID-19, SARS-CoV-2
- Innate and adaptive immune responses to viral infections in general
- DMTs and the SARS-CoV-2 elicited cytokine storm
- The potential effects of DMTs on immune responses to SARS-CoV-2 infection
- Conclusion
- Study funding
- Disclosure
- Appendix Authors
- Footnotes
- References
- Figures & Data
- Info & Disclosures
Related Articles
- No related articles found.